Ascentage Pharma Group International (AAPG) Invested Capital (2022 - 2024)

Historic Invested Capital for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q4 2024 value amounting to $266.2 million.

  • Ascentage Pharma Group International's Invested Capital rose 398.15% to $266.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $266.2 million, marking a year-over-year increase of 398.15%. This contributed to the annual value of $266.2 million for FY2024, which is 206.0% up from last year.
  • Latest data reveals that Ascentage Pharma Group International reported Invested Capital of $266.2 million as of Q4 2024, which was up 398.15% from $256.0 million recorded in Q4 2023.
  • In the past 5 years, Ascentage Pharma Group International's Invested Capital ranged from a high of $307.1 million in Q4 2022 and a low of $256.0 million during Q4 2023
  • Its 3-year average for Invested Capital is $276.5 million, with a median of $266.2 million in 2024.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 1662.54% in 2023, then skyrocketed by 398.15% in 2024.
  • Over the past 3 years, Ascentage Pharma Group International's Invested Capital (Quarter) stood at $307.1 million in 2022, then fell by 16.63% to $256.0 million in 2023, then increased by 3.98% to $266.2 million in 2024.
  • Its last three reported values are $266.2 million in Q4 2024, $256.0 million for Q4 2023, and $307.1 million during Q4 2022.